APO Research
Talk to an analyst

APO RESEARCH · REPORT

Autoimmune Disease Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Autoimmune Disease Drug Market Analysis and Forecast 2026-2032

2 January 2026190 pages

Choose your research edition.

Industry ResearchAutoimmune Disease Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Autoimmune Disease Drug Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Autoimmune Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Autoimmune Disease Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Autoimmune Disease Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Autoimmune Disease Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Autoimmune Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Autoimmune Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Autoimmune Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Autoimmune Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Autoimmune Disease Drug include Roche, Eli Lilly, Pfizer, GlaxoSmithKline, Amgen, AbbVie, Bristol-Myers Squibb, Biogen and AstraZeneca plc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Autoimmune Disease Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Autoimmune Disease Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Autoimmune Disease Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Autoimmune Disease Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Autoimmune Disease Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Autoimmune Disease Drug revenue, projected growth trends, production technology, application and end-user industry.

Autoimmune Disease Drug Segment by Company

Roche

Eli Lilly

Pfizer

GlaxoSmithKline

Amgen

AbbVie

Bristol-Myers Squibb

Biogen

AstraZeneca plc

Abbott Laboratories

Autoimmune Disease Drug Segment by Type

NSAIDs

Interferons

Antihyperglycemics

Anti-Inflammatory

Others

Autoimmune Disease Drug Segment by Application

Psoriasis

Inflammatory Bowel Disease

Rheumatoid Arthritis

Lupus

Multiple Sclerosis

Type 1 Diabetes

Others

Autoimmune Disease Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Autoimmune Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Autoimmune Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Autoimmune Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Autoimmune Disease Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Autoimmune Disease Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Autoimmune Disease Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Autoimmune Disease Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. NSAIDs Major Player Table 3. Interferons Major Player Table 4. Antihyperglycemics Major Player Table 5. Anti-Inflammatory Major Player Table 6. Others Major Player Table 7. Global Autoimmune Disease Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Psoriasis Major Player Table 9. Inflammatory Bowel Disease Major Player Table 10. Rheumatoid Arthritis Major Player Table 11. Lupus Major Player Table 12. Multiple Sclerosis Major Player Table 13. Type 1 Diabetes Major Player Table 14. Others Major Player Table 15. Autoimmune Disease Drug Industry Trends Table 16. Autoimmune Disease Drug Industry Drivers Table 17. Autoimmune Disease Drug Industry Opportunities and Challenges Table 18. Autoimmune Disease Drug Industry Restraints Table 19. Global Autoimmune Disease Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 20. Global Autoimmune Disease Drug Market Size by Region (2021-2026) & (US$ Million) Table 21. Global Autoimmune Disease Drug Market Share by Region (2021-2026) Table 22. Global Autoimmune Disease Drug Market Size by Region (2027-2032) & (US$ Million) Table 23. Global Autoimmune Disease Drug Market Share by Region (2027-2032) Table 24. Global Autoimmune Disease Drug Revenue by Players (US$ Million) & (2021-2026) Table 25. Global Autoimmune Disease Drug Revenue Market Share by Players (2021-2026) Table 26. Global Autoimmune Disease Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 27. Global Autoimmune Disease Drug Key Players Headquarters & Area Served Table 28. Global Autoimmune Disease Drug Players, Product Type & Application Table 29. Global Autoimmune Disease Drug Players Establishment Date Table 30. Global Players Market Concentration Ratio (CR5 and HHI) Table 31. Global Autoimmune Disease Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Autoimmune Disease Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Autoimmune Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Autoimmune Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Autoimmune Disease Drug Revenue Market Share by Type (2021-2026) Table 36. Global Autoimmune Disease Drug Revenue Market Share by Type (2027-2032) Table 37. Global Autoimmune Disease Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Autoimmune Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 39. Global Autoimmune Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 40. Global Autoimmune Disease Drug Revenue Market Share by Application (2021-2026) Table 41. Global Autoimmune Disease Drug Revenue Market Share by Application (2027-2032) Table 42. Roche Company Information Table 43. Roche Business Overview Table 44. Roche Autoimmune Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Roche Autoimmune Disease Drug Product Portfolio Table 46. Roche Recent Development Table 47. Eli Lilly Company Information Table 48. Eli Lilly Business Overview Table 49. Eli Lilly Autoimmune Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Eli Lilly Autoimmune Disease Drug Product Portfolio Table 51. Eli Lilly Recent Development Table 52. Pfizer Company Information Table 53. Pfizer Business Overview Table 54. Pfizer Autoimmune Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Pfizer Autoimmune Disease Drug Product Portfolio Table 56. Pfizer Recent Development Table 57. GlaxoSmithKline Company Information Table 58. GlaxoSmithKline Business Overview Table 59. GlaxoSmithKline Autoimmune Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. GlaxoSmithKline Autoimmune Disease Drug Product Portfolio Table 61. GlaxoSmithKline Recent Development Table 62. Amgen Company Information Table 63. Amgen Business Overview Table 64. Amgen Autoimmune Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Amgen Autoimmune Disease Drug Product Portfolio Table 66. Amgen Recent Development Table 67. AbbVie Company Information Table 68. AbbVie Business Overview Table 69. AbbVie Autoimmune Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. AbbVie Autoimmune Disease Drug Product Portfolio Table 71. AbbVie Recent Development Table 72. Bristol-Myers Squibb Company Information Table 73. Bristol-Myers Squibb Business Overview Table 74. Bristol-Myers Squibb Autoimmune Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Bristol-Myers Squibb Autoimmune Disease Drug Product Portfolio Table 76. Bristol-Myers Squibb Recent Development Table 77. Biogen Company Information Table 78. Biogen Business Overview Table 79. Biogen Autoimmune Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Biogen Autoimmune Disease Drug Product Portfolio Table 81. Biogen Recent Development Table 82. AstraZeneca plc Company Information Table 83. AstraZeneca plc Business Overview Table 84. AstraZeneca plc Autoimmune Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. AstraZeneca plc Autoimmune Disease Drug Product Portfolio Table 86. AstraZeneca plc Recent Development Table 87. Abbott Laboratories Company Information Table 88. Abbott Laboratories Business Overview Table 89. Abbott Laboratories Autoimmune Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 90. Abbott Laboratories Autoimmune Disease Drug Product Portfolio Table 91. Abbott Laboratories Recent Development Table 92. North America Autoimmune Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 93. North America Autoimmune Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 94. North America Autoimmune Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 95. North America Autoimmune Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 96. North America Autoimmune Disease Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. North America Autoimmune Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 98. North America Autoimmune Disease Drug Revenue by Country (US$ Million) & (2027-2032) Table 99. Europe Autoimmune Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 100. Europe Autoimmune Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 101. Europe Autoimmune Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 102. Europe Autoimmune Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 103. Europe Autoimmune Disease Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. Europe Autoimmune Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 105. Europe Autoimmune Disease Drug Revenue by Country (US$ Million) & (2027-2032) Table 106. China Autoimmune Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 107. China Autoimmune Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 108. China Autoimmune Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 109. China Autoimmune Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 110. Asia Autoimmune Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 111. Asia Autoimmune Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 112. Asia Autoimmune Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 113. Asia Autoimmune Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Autoimmune Disease Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 115. Asia Autoimmune Disease Drug Revenue by Region (US$ Million) & (2021-2026) Table 116. Asia Autoimmune Disease Drug Revenue by Region (US$ Million) & (2027-2032) Table 117. SAMEA Autoimmune Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 118. SAMEA Autoimmune Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 119. SAMEA Autoimmune Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 120. SAMEA Autoimmune Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 121. SAMEA Autoimmune Disease Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. SAMEA Autoimmune Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 123. SAMEA Autoimmune Disease Drug Revenue by Country (US$ Million) & (2027-2032) Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Autoimmune Disease Drug Image Figure 2. Global Autoimmune Disease Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Autoimmune Disease Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. NSAIDs Image Figure 5. Interferons Image Figure 6. Antihyperglycemics Image Figure 7. Anti-Inflammatory Image Figure 8. Others Image Figure 9. Global Autoimmune Disease Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Autoimmune Disease Drug Market Size Share 2021 VS 2025 VS 2032 Figure 11. Psoriasis Image Figure 12. Inflammatory Bowel Disease Image Figure 13. Rheumatoid Arthritis Image Figure 14. Lupus Image Figure 15. Multiple Sclerosis Image Figure 16. Type 1 Diabetes Image Figure 17. Others Image Figure 18. Global Autoimmune Disease Drug Market Size (US$ Million) & (2021-2032) Figure 19. Global Autoimmune Disease Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 20. Global Autoimmune Disease Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 21. Global Autoimmune Disease Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Autoimmune Disease Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Autoimmune Disease Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Autoimmune Disease Drug Revenue Market Share by Type (2021-2032) Figure 26. Global Autoimmune Disease Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Autoimmune Disease Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 28. Global Autoimmune Disease Drug Revenue Market Share by Application (2021-2032) Figure 29. North America Autoimmune Disease Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. North America Autoimmune Disease Drug Revenue Share by Type (2021-2032) Figure 31. North America Autoimmune Disease Drug Revenue Share by Application (2021-2032) Figure 32. North America Autoimmune Disease Drug Revenue Share by Country (2021-2032) Figure 33. United States Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Canada Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Mexico Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Europe Autoimmune Disease Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 37. Europe Autoimmune Disease Drug Revenue Share by Type (2021-2032) Figure 38. Europe Autoimmune Disease Drug Revenue Share by Application (2021-2032) Figure 39. Europe Autoimmune Disease Drug Revenue Share by Country (2021-2032) Figure 40. Germany Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. France Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. U.K. Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Italy Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Spain Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Russia Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. Netherlands Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 47. Nordic Countries Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. China Autoimmune Disease Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. China Autoimmune Disease Drug Revenue Share by Type (2021-2032) Figure 50. China Autoimmune Disease Drug Revenue Share by Application (2021-2032) Figure 51. Asia Autoimmune Disease Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 52. Asia Autoimmune Disease Drug Revenue Share by Type (2021-2032) Figure 53. Asia Autoimmune Disease Drug Revenue Share by Application (2021-2032) Figure 54. Asia Autoimmune Disease Drug Revenue Share by Region (2021-2032) Figure 55. Japan Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. South Korea Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. India Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Australia Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Taiwan Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Southeast Asia Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. SAMEA Autoimmune Disease Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 62. SAMEA Autoimmune Disease Drug Revenue Share by Type (2021-2032) Figure 63. SAMEA Autoimmune Disease Drug Revenue Share by Application (2021-2032) Figure 64. SAMEA Autoimmune Disease Drug Revenue Share by Country (2021-2032) Figure 65. Brazil Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Argentina Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Chile Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Colombia Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Peru Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Saudi Arabia Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Israel Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. UAE Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Turkey Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Iran Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 75. Egypt Autoimmune Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • NSAIDs
  • Interferons
  • Antihyperglycemics
  • Anti-Inflammatory
  • Others
Applications
  • Psoriasis
  • Inflammatory Bowel Disease
  • Rheumatoid Arthritis
  • Lupus
  • Multiple Sclerosis
  • Type 1 Diabetes
  • Others
Companies covered
  • Roche
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • Amgen
  • AbbVie
  • Bristol-Myers Squibb
  • Biogen
  • AstraZeneca plc
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Autoimmune Disease Drug Market by Type
  3. 1.2.1 Global Autoimmune Disease Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 NSAIDs
  5. 1.2.3 Interferons
  6. 1.2.4 Antihyperglycemics
  7. 1.2.5 Anti-Inflammatory
  8. 1.2.6 Others
  9. 1.3 Autoimmune Disease Drug Market by Application
  10. 1.3.1 Global Autoimmune Disease Drug Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Psoriasis
  12. 1.3.3 Inflammatory Bowel Disease
  13. 1.3.4 Rheumatoid Arthritis
  14. 1.3.5 Lupus
  15. 1.3.6 Multiple Sclerosis
  16. 1.3.7 Type 1 Diabetes
  17. 1.3.8 Others
  18. 1.4 Assumptions and Limitations
  19. 1.5 Study Goals and Objectives
2 Autoimmune Disease Drug Market Dynamics
  1. 2.1 Autoimmune Disease Drug Industry Trends
  2. 2.2 Autoimmune Disease Drug Industry Drivers
  3. 2.3 Autoimmune Disease Drug Industry Opportunities and Challenges
  4. 2.4 Autoimmune Disease Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Autoimmune Disease Drug Market Perspective (2021-2032)
  2. 3.2 Global Autoimmune Disease Drug Growth Trends by Region
  3. 3.2.1 Global Autoimmune Disease Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Autoimmune Disease Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Autoimmune Disease Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Autoimmune Disease Drug Revenue by Players
  2. 4.1.1 Global Autoimmune Disease Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Autoimmune Disease Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Autoimmune Disease Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Autoimmune Disease Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Autoimmune Disease Drug Key Players Headquarters & Area Served
  7. 4.4 Global Autoimmune Disease Drug Players, Product Type & Application
  8. 4.5 Global Autoimmune Disease Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Autoimmune Disease Drug Market CR5 and HHI
  11. 4.6.3 2025 Autoimmune Disease Drug Tier 1, Tier 2, and Tier 3
5 Autoimmune Disease Drug Market Size by Type
  1. 5.1 Global Autoimmune Disease Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Autoimmune Disease Drug Revenue by Type (2021-2032)
  3. 5.3 Global Autoimmune Disease Drug Revenue Market Share by Type (2021-2032)
6 Autoimmune Disease Drug Market Size by Application
  1. 6.1 Global Autoimmune Disease Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Autoimmune Disease Drug Revenue by Application (2021-2032)
  3. 6.3 Global Autoimmune Disease Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Roche
  2. 7.1.1 Roche Company Information
  3. 7.1.2 Roche Business Overview
  4. 7.1.3 Roche Autoimmune Disease Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Roche Autoimmune Disease Drug Product Portfolio
  6. 7.1.5 Roche Recent Developments
  7. 7.2 Eli Lilly
  8. 7.2.1 Eli Lilly Company Information
  9. 7.2.2 Eli Lilly Business Overview
  10. 7.2.3 Eli Lilly Autoimmune Disease Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Eli Lilly Autoimmune Disease Drug Product Portfolio
  12. 7.2.5 Eli Lilly Recent Developments
  13. 7.3 Pfizer
  14. 7.3.1 Pfizer Company Information
  15. 7.3.2 Pfizer Business Overview
  16. 7.3.3 Pfizer Autoimmune Disease Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer Autoimmune Disease Drug Product Portfolio
  18. 7.3.5 Pfizer Recent Developments
  19. 7.4 GlaxoSmithKline
  20. 7.4.1 GlaxoSmithKline Company Information
  21. 7.4.2 GlaxoSmithKline Business Overview
  22. 7.4.3 GlaxoSmithKline Autoimmune Disease Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 GlaxoSmithKline Autoimmune Disease Drug Product Portfolio
  24. 7.4.5 GlaxoSmithKline Recent Developments
  25. 7.5 Amgen
  26. 7.5.1 Amgen Company Information
  27. 7.5.2 Amgen Business Overview
  28. 7.5.3 Amgen Autoimmune Disease Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Amgen Autoimmune Disease Drug Product Portfolio
  30. 7.5.5 Amgen Recent Developments
  31. 7.6 AbbVie
  32. 7.6.1 AbbVie Company Information
  33. 7.6.2 AbbVie Business Overview
  34. 7.6.3 AbbVie Autoimmune Disease Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 AbbVie Autoimmune Disease Drug Product Portfolio
  36. 7.6.5 AbbVie Recent Developments
  37. 7.7 Bristol-Myers Squibb
  38. 7.7.1 Bristol-Myers Squibb Company Information
  39. 7.7.2 Bristol-Myers Squibb Business Overview
  40. 7.7.3 Bristol-Myers Squibb Autoimmune Disease Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Bristol-Myers Squibb Autoimmune Disease Drug Product Portfolio
  42. 7.7.5 Bristol-Myers Squibb Recent Developments
  43. 7.8 Biogen
  44. 7.8.1 Biogen Company Information
  45. 7.8.2 Biogen Business Overview
  46. 7.8.3 Biogen Autoimmune Disease Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Biogen Autoimmune Disease Drug Product Portfolio
  48. 7.8.5 Biogen Recent Developments
  49. 7.9 AstraZeneca plc
  50. 7.9.1 AstraZeneca plc Company Information
  51. 7.9.2 AstraZeneca plc Business Overview
  52. 7.9.3 AstraZeneca plc Autoimmune Disease Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 AstraZeneca plc Autoimmune Disease Drug Product Portfolio
  54. 7.9.5 AstraZeneca plc Recent Developments
  55. 7.10 Abbott Laboratories
  56. 7.10.1 Abbott Laboratories Company Information
  57. 7.10.2 Abbott Laboratories Business Overview
  58. 7.10.3 Abbott Laboratories Autoimmune Disease Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Abbott Laboratories Autoimmune Disease Drug Product Portfolio
  60. 7.10.5 Abbott Laboratories Recent Developments
8 North America
  1. 8.1 North America Autoimmune Disease Drug Revenue (2021-2032)
  2. 8.2 North America Autoimmune Disease Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Autoimmune Disease Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Autoimmune Disease Drug Revenue by Type (2027-2032)
  5. 8.3 North America Autoimmune Disease Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Autoimmune Disease Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Autoimmune Disease Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Autoimmune Disease Drug Revenue by Application (2027-2032)
  9. 8.5 North America Autoimmune Disease Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Autoimmune Disease Drug Revenue by Country
  11. 8.6.1 North America Autoimmune Disease Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Autoimmune Disease Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Autoimmune Disease Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Autoimmune Disease Drug Revenue (2021-2032)
  2. 9.2 Europe Autoimmune Disease Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Autoimmune Disease Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Autoimmune Disease Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Autoimmune Disease Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Autoimmune Disease Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Autoimmune Disease Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Autoimmune Disease Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Autoimmune Disease Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Autoimmune Disease Drug Revenue by Country
  11. 9.6.1 Europe Autoimmune Disease Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Autoimmune Disease Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Autoimmune Disease Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Autoimmune Disease Drug Revenue (2021-2032)
  2. 10.2 China Autoimmune Disease Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Autoimmune Disease Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Autoimmune Disease Drug Revenue by Type (2027-2032)
  5. 10.3 China Autoimmune Disease Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Autoimmune Disease Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Autoimmune Disease Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Autoimmune Disease Drug Revenue by Application (2027-2032)
  9. 10.5 China Autoimmune Disease Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Autoimmune Disease Drug Revenue (2021-2032)
  2. 11.2 Asia Autoimmune Disease Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Autoimmune Disease Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Autoimmune Disease Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Autoimmune Disease Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Autoimmune Disease Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Autoimmune Disease Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Autoimmune Disease Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Autoimmune Disease Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Autoimmune Disease Drug Revenue by Country
  11. 11.6.1 Asia Autoimmune Disease Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Autoimmune Disease Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Autoimmune Disease Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Autoimmune Disease Drug Revenue (2021-2032)
  2. 12.2 SAMEA Autoimmune Disease Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Autoimmune Disease Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Autoimmune Disease Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Autoimmune Disease Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Autoimmune Disease Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Autoimmune Disease Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Autoimmune Disease Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Autoimmune Disease Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Autoimmune Disease Drug Revenue by Country
  11. 12.6.1 SAMEA Autoimmune Disease Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Autoimmune Disease Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Autoimmune Disease Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst